IP Library Granted Patent US 12,293,295
Granted Patent B2
US 12,293,295 · App. 17/753,931 · Granted May 6, 2025

Histological image analysis

Inventors: Sepp De Raedt (Oslo, NO); Ole-Johan Skrede (Oslo, NO); Håvard Emil Greger Danielsen (Oslo, NO); Tarjei Sveinsgjerd Hveem (Oslo, NO); Andreas Kleppe (Oslo, NO); Knut Liestøl (Oslo, NO)
Assignee: OSLO UNIVERSITETSSYKEHUS
G06N3/084A61B5/4848A61B34/10G06T7/0016G06V10/26G06V10/454G06V10/774G06V10/776G06V10/80G06V10/82G06V10/87G06V20/695G06V20/698G06V20/70G06V30/2504G16H50/20G06T2207/20021G06T2207/20081G06T2207/20084G06T2207/30024G06V2201/03
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,293,295
App. No.
17/753,931
Granted
May 6, 2025
Kind
B2
Abstract

A computer implemented system for determining an overall-classifier for one or more source-histological-images. The system comprising: a first tile generator ( 204 ) configured to generate a plurality of first-tiles ( 206; 306 ) from the one or more source-histological-image ( 202; 302 ); and a second tile generator ( 205 ) configured to generate a plurality of second-tiles ( 207; 307 ) from the one or more source-histological-images ( 202; 302 ). The first-area of the first-tiles ( 206; 306 ) is larger than the second-area of the second-tiles ( 207; 307 ); and the second-resolution of the second-tiles ( 207; 307 ) is higher than the first-resolution of the first-tiles ( 206; 306 ). The system also includes a machine-learning network ( 211; 311 ) configured to process the plurality of first-tiles ( 206; 306 ) in order to determine a first-classifier ( 218; 318 ); a machine-learning network ( 215; 311 ) configured to process the plurality of second-tiles ( 207; 307 ) in order to determine a second-classifier ( 219; 319 ); and a classifier combiner configured to combine the first-classifier ( 218; 318 ) and the second-classifier ( 219; 319 ) to determine the overall-classifier ( 232; 332 ).

Claims (65)

1. A computer implemented system for determining an overall-classifier of one or more source-histopathological-images, wherein each source-histopathological-image has been obtained from one or more histopathological samples obtained from one or more subjects, and wherein each subject has been diagnosed as having, is suspected of having, is being treated for, has previously been treated for, and/or has previously had, cancer, the system comprising:

a first tile generator configured to generate a plurality of first-tiles from the one or more source-histopathological-images, wherein each of the plurality of first-tiles comprises a plurality of pixels that represents a region of the one or more source-histopathological-images having a first-area and a first-resolution;

a second tile generator configured to generate a plurality of second-tiles from the one or more source-histopathological-images, wherein each of the plurality of second-tiles comprises a plurality of pixels that represents a region of the one or more source-histopathological-images having a second-area and a second-resolution, wherein:

the first-area of the first-tiles is larger than the second-area of the second-tiles; and

the second-resolution of the second-tiles is higher than the first-resolution of the first-tiles;

a first machine-learning network configured to process the plurality of first-tiles in order to determine a first-classifier for the one or more source-histopathological-images, wherein the first machine-learning network ( 311 ) comprises:

a first-neural-network configured to process the plurality of first-tiles in order to determine a tile-feature for each of the plurality of first-tiles;

a pooling-function configured to combine subsets of the tile-features to generate a bag-feature for each of the subsets; and

a second-neural-network configured to process the bag-features in order to determine a first-classifier for the one or more source-histopathological-images, wherein the second-neural-network is a classification network;

a second machine-learning network configured to process the plurality of second-tiles in order to determine a second-classifier for the one or more source-histopathological-images, wherein the second machine-learning network comprises:

a first neural-network configured to process the plurality of second-tiles in order to determine a tile-feature for each of the plurality of second-tiles;

a pooling-function configured to combine subsets of the tile-features to generate a bag-feature for each of the subsets; and

a second-neural-network configured to process the bag-features in order to determine a second-classifier for the one or more source-histopathological-images, wherein the second-neural-network is a classification network; and

a classifier combiner configured to combine the first-classifier and the second-classifier to determine the overall-classifier for the one or more source-histopathological-images.

2. The system of claim 1 , wherein the classifier combiner is configured to:

apply a thresholding function to the first-classifier in order to determine a thresholded-first-classifier;

apply a thresholding function to the second-classifier in order to determine a thresholded-second-classifier; and

combine the thresholded-first-classifier and the thresholded-second-classifier to determine the overall-classifier.

3. The system of claim 1 , wherein:

the first machine-learning network is configured to process the plurality of first-tiles in order to determine a plurality of first-classifiers for the one or more source-histopathological-images;

the second machine-learning network is configured to process the plurality of second-tiles in order to determine a plurality of second-classifiers for the one or more source-histopathological-images; and

the classifier combiner is configured to:

apply a statistical function to the plurality of first-classifiers in order to determine a combined-first-classifier;

apply a statistical function to the plurality of second-classifiers in order to determine a combined-second-classifier;

combine the combined-first-classifier and the combined-second-classifier to determine the overall-classifier.

4. The system of claim 1 , wherein the classifier combiner is configured to perform a logical combination of the first-classifier and the second-classifier to determine the overall-classifier for the one or more source-histopathological-images.

5. The system of claim 1 , wherein the first machine-learning network, the second machine-learning network, or both the first and second machine-learning networks-further comprise:

a loss-function configured to:

compare the classifier that is determined by the second-neural-network with a ground-truth that is represented by truth-data, and

set trainable parameters for the first-neural-network, the pooling-function, and the second-neural-network based on the result of the comparison.

6. The system of claim 1 , further comprising:

a segmentation block that is configured to apply an image segmentation method to a whole-slide-image-histopathological image in order to provide a source-histopathological-image.

7. The system according to claim 1 , wherein the first tile generator and the second tile generator are configured to generate their respective tiles independently of one another.

8. The system according to claim 1 , wherein:

at least one of the first machine-learning networks and second machine-learning networks have been trained using training-histopathological-images and associated ground-truths, and

the one or more training-histopathological-images has been obtained from one or more histopathological samples obtained from one or more subjects, and wherein each subject has, has been diagnosed as having, is suspected of having, is being treated for, has previously been treated for, and/or has previously had, cancer.

9. The system of claim 1 , wherein the cancer is selected from the group consisting of carcinoma, sarcoma, myeloma, leukemia, lymphoma and a mixed type of cancer.

10. The system of claim 9 , wherein the cancer is a colorectal cancer, or lung cancer.

11. A computer implemented method of determining an overall-classifier for one or more source-histopathological-images, the method comprising:

generating a plurality of first-tiles from the one or more source-histopathological-images, wherein each of the plurality of first-tiles comprises a plurality of pixels that represents a region of the one or more source-histopathological-images having a first-area and a first-resolution;

generating a plurality of second-tiles from the one or more source-histopathological-images, wherein each of the plurality of second-tiles comprises a plurality of pixels that represents a region of the one or more source-histopathological-images having a second-area and a second-resolution, wherein:

the first-area of the first-tiles is larger than the second-area of the second-tiles; and

the second-resolution of the second-tiles is higher than the first-resolution of the first-tiles;

applying a first machine-learning network to the plurality of first-tiles in order to determine a first-classifier for the one or more source-histopathological-images, wherein applying the first machine-learning network comprises:

applying a first-neural-network to the plurality of first-tiles in order to determine a tile-feature for each of the plurality of first-tiles;

combining subsets of the tile-features to generate a bag-feature for each of the subsets; and

applying a second-neural-network to the bag-features in order to determine a first-classifier for the one or more source-histopathological-images, wherein the second-neural-network is a classification network;

applying a second machine-learning network to the plurality of second-tiles in order to determine a second-classifier for the one or more source-histopathological-images, wherein applying the second machine-learning network comprises:

applying a first-neural-network to the plurality of second-tiles in order to determine a tile-feature for each of the plurality of second-tiles;

combining subsets of the tile-features to generate a bag-feature for each of the subsets; and

applying a second-neural-network to the bag-features in order to determine a second-classifier for the one or more source-histopathological-images, wherein the second-neural-network is a classification network; and

combining the first-classifier and the second-classifier to determine the overall-classifier for the one or more source-histopathological-images.

12. The computer implemented method of processing one claim 11 , and wherein the method further comprises:

attributing a diagnostic and/or prognostic evaluation to the classifier and/or overall-classifier.

13. The computer-implemented method of claim 12 , wherein the subject is a human.

14. The computer-implemented method of claim 12 , wherein the one or more histopathological samples obtained from the subject is, or are, obtained from the part of the subject's body that has, is suspected of having, is being treated for, has been treated for, and/or has previously had, cancer.

15. The computer-implemented method of claim 12 , wherein the method comprises assessing a plurality of source-histopathological-images obtained from a plurality of histopathological samples obtained from the subject in order to determine a plurality of classifiers and/or overall-classifiers, and: optionally attributing the diagnostic and/or prognostic evaluation to the plurality of classifiers and/or overall-classifiers.

16. The computer-implemented method of claim 12 , wherein the method comprises assessing one or more further diagnostic and/or prognostic markers for the cancer, and wherein the step of attributing a diagnostic and/or prognostic evaluation to the classifier and/or overall-classifier includes an assessment of the or each of the results of the assessment of the or each further diagnostic and/or prognostic markers.

17. The computer-implemented method of claim 12 , wherein the method further comprises making a treatment decision for the subject on the basis of the diagnostic and/or prognostic evaluation, optionally wherein the treatment decision is in respect of a diagnosed or prognosed cancer condition, for example a cancer selected from the group consisting of carcinoma, sarcoma, myeloma, leukemia, lymphoma and a mixed type of cancer, and optionally wherein the cancer is a colorectal cancer or lung cancer.

18. The computer-implemented method of claim 17 , wherein the diagnostic and/or prognostic evaluation of the subject includes the assessment of the effect on the subject of an earlier, or ongoing, treatment by surgery and/or non-surgical therapy, for example, in order to monitor the progress and/or effect of such treatment, and further optionally wherein the method includes the step of making a further treatment decision, such as the cessation, continuation, repetition or modification an earlier, or ongoing, treatment and/or the implementation of a different treatment modality, and optionally, implementing that further treatment decision in respect of the subject; wherein: the diagnostic and/or prognostic evaluation, the treatment and/or the treatment decision is in respect of a cancer condition, for example a cancer selected from the group consisting of carcinoma, sarcoma, myeloma, leukemia, lymphoma and a mixed type of cancer, and optionally wherein the cancer is a colorectal cancer.

19. The computer-implemented method of claim 12 , the method comprising treating the subject by a method of surgery and/or non-surgical therapy; wherein the treatment for the diagnosed or prognosed pathological condition is for the treatment of cancer, for example a cancer selected from the group consisting of carcinoma, sarcoma, myeloma, leukemia, lymphoma and a mixed type of cancer, and optionally wherein the cancer is a colorectal cancer or lung cancer.

20. The computer-implemented method of claim 19 , wherein the subject is a human.

21. The computer-implemented method of claim 19 , wherein the subject: (a) has, has been diagnosed as having, is suspected of having, is being treated for, has previously been treated for, and/or has previously had, cancer; and/or (b) wherein a diagnostic and/or prognostic evaluation of a cancer condition has been attributed to the subject by a method according to any of claims 10 to 17 .

22. The computer-implemented method of claim 21 , wherein the pathological condition is a cancer selected from the group consisting of carcinoma, sarcoma, myeloma, leukemia, lymphoma and a mixed type of cancer, and optionally wherein the cancer is a colorectal cancer or lung cancer.

23. The computer-implemented method of claim 19 , wherein the method comprises adapting one or more parameters of the surgery and/or non-surgical therapy in view of the diagnostic and/or prognostic evaluation that has been attributed to the subject by a method according to any of claims 10 to 17 , and optionally wherein the one or more parameters of the surgery and/or non-surgical therapy are selected from the group consisting of the nature of the surgery and/or non-surgical therapy, the timing of the surgery and/or non-surgical therapy, period of the surgery and/or non-surgical therapy, the dosage of the therapy, the route of administration of the non-surgical therapy, and the site(s) in the body that is targeted by the surgery and/or non-surgical therapy.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2022
From: RAEDT, SEPP DE; SKREDE, OLE-JOHAN; DANIELSEN, HÅVARD EMIL GREGER; HVEEM, TARJEI SVEINSGJERD; KLEPPE, ANDREAS; LIESTØL, KNUT
To: OSLO UNIVERSITETSSYKEHUS
Reel/Frame 060410/0735 →
Priority Claims (1)
GB 1913616 · Sep 20, 2019 · national
Continuity (1)
Related Publication 20240037747A1 · Feb 1, 2024
References Cited (38)
US 20170161891A1 · Madabhushi et al. · 2017 [cited by applicant]
US 20190156159A1 · Kopparapu · 2019 [cited by applicant]
US 20210271847A1 · Courtiol · 2021 [cited by examiner]
CN 107886127A · 2018 [cited by applicant]
CN 110023994A · 2019 [cited by applicant]
CN 105027165 · 2021 [cited by applicant]
JP 2019148473A · 2019 [cited by applicant]
Campanella, et al., Campanella, G., Hanna, M.G., Geneslaw, L. et al. Clinical-grade computational pathology using weakly supervised deep learning on whole slide images. Nat Med 25, 1301-1309 (2019). https://doi.org/10.1… [cited by applicant]
Das, et al., “Classifying histopathology whole-slides using fusion of decisions from deep convolutional network on a collection of random multi-views at multi-magnification,” 2017 IEEE 14th (ISBI 2017), 2017, pp. 1024-1… [cited by applicant]
Das, et al., K. Das et al., “Multiple instance learning of deep convolutional neural networks for breast histopathology whole slide classification,” 2018 IEEE 15th (ISBI 2018), 2018, pp. 578-581, doi: 10.1109/ISBI.2018.… [cited by applicant]
Hou, et al., L. Hou et al. “Patch-Based Convolutional Neural Network for Whole Slide Tissue Image Classification,” 2016 IEEE Conference on CVPR, 2016, pp. 2424-2433 doi: 10.1109/CVPR.2016.266. [cited by applicant]
Kraus, et al., Oren Z. Kraus, Jimmy Lei Ba, Brendan J. Frey, Classifying and segmenting microscopy images with deep multiple instance learning, Bioinformatics, vol. 32, Issue 12, Jun. 15, 2016, pp. i52-i59, https://doi.… [cited by applicant]
Mobadersany, et al., Mobadersany et al., “Predicting cancer outcomes from histology and genomics using convolutional networks”, Proceedings of the National Academy of Sciences, Mar. 27, 2018 National Academy of Sciences… [cited by applicant]
Skrede, et al., “Deep learning for prediction of colorectal cancer outcome: a discovery and validation study” The Lancet, vol. 395, No. 10221, Jan. 30, 2020 (Jan. 30, 2020), pp. 350-360, XP086024041, https://doi.org/10.… [cited by applicant]
International Search Report and Written Opinion for PCT/EP2020/076090, mailed Dec. 11, 2020. [cited by applicant]
“Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial”, QUASAR Collaborative Group, The Lancet, vol. 355., May 6, 2… [cited by applicant]
Bejnordi, et al., “Diagnostic Assessment of Deep Learning Algorithms for Detection of Lymph Node Metastases in Women With Breast Cancer”, 2017 American Medical Association, JAMA. 2017;318(22):2199-2210. doi:10.1001/jama… [cited by applicant]
Bychkov, et al., “Deep learning based tissue analysis predicts outcome in colorectal cancer”, Scientific Reports, 2018, DOI:10.1038/s41598-018-21758-3, www.nature.com/scientificreports/. [cited by applicant]
Coudray, et al., “Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning”, Nature Medicine, https://doi.org/10.1038/s41591-018-0177-5, www.nature.com/naturemedic… [cited by applicant]
Couture, et al., “Multiple Instance Learning for Heterogeneous Images: Training a CNN for Histopathology”, Springer Nature Switzerland AG 2018, A. F. Frangi et al. (Eds.): MICCAI 2018, LNCS 11071, pp. 254-262, 2018. htt… [cited by applicant]
Danielsen, et al., “Prognostic markers for colorectal cancer: estimating ploidy and stroma”, Annals of Oncology 29: 616-623, 2018, doi:10.1093/annonc/mdx794, Dec. 27, 2017, 616-623. [cited by applicant]
Gray, et al., “Validation Study of a Quantitative Multigene Reverse Transcriptase-Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer”, American Society of Clinical O… [cited by applicant]
Karapetis, et al., “K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer”, The New England Journal of Medicine, Massachusetts Medical Society., Oct. 23, 2008, 1757-1765. [cited by applicant]
Kather, et al., “Predicting survival from colorectal cancer histology slides using deep learning: A retrospective multicenter study”, PLoS Med 16(1): e1002730. https://doi.org/10.1371/journal.pmed.1002730. [cited by applicant]
Kerr, et al., “Tailoring treatment and trials to prognosis”, Nat. Rev. Clin. Oncol. 10, 429-430 (2013); published online Jun. 11, 2013; doi:10.1038/nrclinonc.2013.97, Aug. 2013, 429-430. [cited by applicant]
La Thangue, et al., “Predictive biomarkers: a paradigm shift towards personalized cancer medicine”, Nature Review, Clinical Oncology, vol. 8, Oct. 2011, pp. 589-596. [cited by applicant]
Liu, et al., “Detecting Cancer Metastases on Gigapixel Pathology Images”, arXiv:1703.02442v2 [cs.CV] Mar. 8, 2017. [cited by applicant]
Sinicrope, “DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer”, Nat. Rev. Clin. Oncol. 7, 174-177 (2010): doi:10.1038/nrclinonc.2009.235, Mar. 2010, 174-177. [cited by applicant]
Tong, et al., “Improving Classification of Breast Cancer by Utilizing the Image Pyramids of Whole-Slide Imaging and Multi-Scale Convolutional Neural Networks”, 2019 IEEE 43rd Annual Computer Software and Applications Co… [cited by applicant]
Andre et al., “Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study”, Journa… [cited by applicant]
Andre , et al., “Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial”, Journal of Clinical Oncology, vol. 27 No. 19, Jul. 1,… [cited by applicant]
Gray , et al., “Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study”, Lancet 2007; 370: 2020-29. [cited by applicant]
Hutchins , et al., “Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer”, Journal of Clinical Oncology, vol. 29 No. 10, Apr. 1, 2011. [cited by applicant]
Moscow, et al., “The evidence framework for precision cancer medicine”, Nature Reviews | Clinical Oncology; vol. 15; Mar. 2018. [cited by applicant]
Mouradov , et al., “Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations”, The American Journal of Gastroenterology, 2… [cited by applicant]
Salazar et al., “Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer”, Journal of Clinical Psychology; vol. 29, No. 1; Jan. 1, 2011. [cited by applicant]
Tokunaga, Hiroki , et al., “Adaptively Weighting Multi-scale FCN”, IPSJ SIG Technical Report, vol. 2018-CVIM No. 24 May 10, 2018. [cited by applicant]
Van Allen , et al., “Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine”, Nature Medicine; vol. 20, No. 6; Jun. 2014. [cited by applicant]